COMPANY

HiberCell

HQ: Roseville, MN source · hibercell.com ↗ · Midwest

Location: Roseville, MN · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Renal Cell Carcinoma Non Small Cell Lung Cancer Colorectal Cancer Recurrent Colorectal Carcinoma Progressive Colorectal Carcinoma Advanced Melanoma Triple-Negative Breast Cancer Metastatic Pancreatic Adenocarcinoma Squamous Cell Carcinoma of Head and Neck Colo-rectal Cancer Transitional Cell Carcinoma of the Bladder Clear Cell Renal Cell Carcinoma Gastric Cancer Metastatic Breast Cancer Small-cell Lung Cancer Malignant Neoplasm of Breast Pathologic Stage III Cutaneous Melanoma AJCC v8 Squamous Cell Carcinoma of the Head and Neck NSCLC HC-7366 Imprime PGG CDX-1140 HC-5404-FU

16Trials (company is sponsor)

Raises and deals from press releases

Deal Merck deal · amount not disclosed · announced Dec 5, 2023 Company release ↗
Source quote
- Dec 5, 2023 · Company release ↗
  “Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC) NEW YORK, Dec. 05, 2023 — HiberCell, Inc.”

From the company’s own releases; this list is partial. All raises and deals

Timeline

Apr 29, 2024 Trial start Phase 1: A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma source ↗
Dec 15, 2022 Trial start Phase 1: A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma source ↗
Feb 23, 2022 Trial start 2: A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) source ↗
Nov 9, 2021 Trial start 2: Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) source ↗
Aug 15, 2021 Trial start Phase 2: Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma source ↗
Jun 8, 2021 Trial start Phase 1: A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) source ↗
Nov 8, 2017 Trial start 2: Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD source ↗
Feb 22, 2017 Trial start Phase 2: Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer source ↗
2011-04 Trial start Phase 3: Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer source ↗
2009-08 Trial start Phase 2: Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer source ↗
2009-06 Trial start Phase 2: Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) source ↗
2009-06 Trial start —: Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer source ↗
2007-10 Trial start Phase 1/Phase 2: Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma source ↗
2006-11 Trial start I: Phase I/II, Randomized, Double-Blind, Study of the Progenitor Cell Mobilizing Effects of Imprime PGG™ Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone source ↗
2006-05 Trial start Phase 1: Multiple-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Imprime PGG™ Injection source ↗
2005-12 Trial start I: Phase Ia Dose-Escalation Safety, Pharmacodynamic and Pharmacokinetic Study of Imprime PGG™ Injection source ↗

Upcoming milestones

2026-11 (ESTIMATED) · Phase 1 · A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma · NCT06234605

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 16

Record	Title	Phase	Status	Start	Primary completion
NCT06234605	A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma	Phase 1	Recruiting	Apr 29, 2024	2026-11 (estimated)
NCT00545545	Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma	Phase 1/Phase 2	Completed	2007-10	2009-12 (actual)
NCT02981303	Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer	Phase 2	Completed	Feb 22, 2017	Dec 31, 2020 (actual)
NCT05484011	A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma	Phase 1	Terminated	Dec 15, 2022	Mar 4, 2024 (actual)
NCT05121948	A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)	2	Terminated	Feb 23, 2022	Feb 9, 2024 (actual)
NCT04834778	A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)	Phase 1	Completed	Jun 8, 2021	Dec 7, 2023 (actual)
NCT05159778	Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)	2	Completed	Nov 9, 2021	Mar 22, 2023 (actual)
NCT04995094	Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma	Phase 2	Withdrawn	Aug 15, 2021	Feb 18, 2023 (estimated)
NCT03246685	Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD	2	Terminated	Nov 8, 2017	Apr 13, 2018 (actual)
NCT01309126	Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer	Phase 3	Terminated	2011-04	2017-02 (actual)
NCT00874107	Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)	Phase 2	Completed	2009-06	2016-04 (actual)
NCT00874848	Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer	Phase 2	Completed	2009-08	2012-11 (actual)
NCT00912327	Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer	Not listed	Completed	2009-06	2012-02 (actual)
NCT00542529	Phase I/II, Randomized, Double-Blind, Study of the Progenitor Cell Mobilizing Effects of Imprime PGG™ Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone	I	Completed	2006-11	Not listed
NCT00542464	Multiple-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Imprime PGG™ Injection	Phase 1	Completed	2006-05	Not listed
NCT00542217	Phase Ia Dose-Escalation Safety, Pharmacodynamic and Pharmacokinetic Study of Imprime PGG™ Injection	I	Completed	2005-12	Not listed

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of ARCH Venture Partners (captured Oct 12, 2026). portfolio page ↗